Compare ATAI & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATAI | ASTH |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2021 | 2015 |
| Metric | ATAI | ASTH |
|---|---|---|
| Price | $3.38 | $24.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $15.13 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 4.4M | 479.2K |
| Earning Date | 03-06-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | $308,000.00 | ★ $519,907,752.00 |
| Revenue This Year | N/A | $27.32 |
| Revenue Next Year | N/A | $10.84 |
| P/E Ratio | ★ N/A | $52.55 |
| Revenue Growth | N/A | ★ 45.90 |
| 52 Week Low | $1.15 | $18.08 |
| 52 Week High | $6.73 | $34.80 |
| Indicator | ATAI | ASTH |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 54.13 |
| Support Level | $3.06 | $23.82 |
| Resistance Level | $4.30 | $25.41 |
| Average True Range (ATR) | 0.21 | 1.07 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 13.33 | 52.81 |
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.